CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Published 2017 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
Authors
Keywords
Palbociclib, Ribociclib, Abemaciclib, CDK 4, CDK 6, CDK 4 inhibitors, CDK 6 inhibitors, CDK4/6 inhibitors, retinoblastoma, retinoblastoma protein, me-too cancer therapies, FDA approvals
Journal
SEMINARS IN ONCOLOGY
Volume 44, Issue 6, Pages 395-403
Publisher
Elsevier BV
Online
2018-03-26
DOI
10.1053/j.seminoncol.2018.03.006

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.